Nuvation Bio

Makes cancer drugs, including the lung cancer pill Ibtrozi.

Company Health

/100

Mixed

A quick check of the business from its yearly reports (2022–2025). It doesn’t say whether the stock is a good buy.

Does it make money?

0 of 25 · Poor

It lost money last year: $325 of every $100 in sales.

Is it growing?

25 of 25 · Good

Sales grew about 700% over the last year.

Can it handle what it owes?

9 of 25 · Poor

Its business used cash last year, and it owes $49 of every $100 it owns.

Who owns it

2 of 23 own it · Nobody changed their stake

bought lately

owns it

doesn’t own it

Didn’t report owning it: Whale Rock, Appaloosa, Melqart, Coatue, D1 Capital, Light Street, Lone Pine, Third Point, TCI, Pershing Square, Himalaya Capital, Giverny Capital, Fundsmith, Semper Augustus, Akre

Their letters don’t mention it: Arquitos, Laughing Water, Alluvial, Bireme, Kingdom Capital, Saga Partners

From each fund’s latest 13F report (Jun 30, 2026). Funds that don’t file one: from their own letters.

The numbers

From Nuvation Bio’s yearly reports. Tap a year to see its figures.

Sales and profit

Sales went from $0 in 2023 to $62.9 million in 2025, and it lost money every year.

2025

Sales

$62.9 million

Loss

$205 million

What it owns and what it owes

At the end of 2025 it owned $595 million, including $164 million in cash, and owed $289 million.

Key facts

From its yearly report for 2025.

Sales

$62.9 million

Loss

$205 million

Cash in the bank

$164 million

Everything it owes

$289 million

Year ends

December

Money shown in

U.S. dollars

Latest yearly report

10-K, filed Mar 2, 2026

Figures from Nuvation Bio’s yearly reports to the SEC (EDGAR), collected Oct 12, 2026.

Not investment advice. Holdings come from public SEC reports and the funds’ own letters, and can be up to 4½ months old. How this works